Theranos
Theranos Fraudulent Blood Testing Technology
Estimated impact: $9B
Theranos claimed to have revolutionized blood testing with proprietary technology that could run hundreds of tests from a single drop of blood. The technology never worked as claimed, yet the company raised over $700 million, reaching a $9 billion valuation as investors and board members deferred to founder Elizabeth Holmes's authority.
Decision context
Whether investors and board members should have demanded independent validation of Theranos's technology claims before investing hundreds of millions of dollars.
The analysis below was produced from the pre-decision document only — no hindsight. This is what the platform would have surfaced if it had been running in 2014-06-15.
“The Edison platform is capable of performing over 200 standard laboratory tests from a single drop of blood drawn from a fingertip. Our proprietary micro-sample technology eliminates the need for traditional venipuncture, making diagnostic testing faster, cheaper, and accessible to millions. We project deployment across 10,000 pharmacy locations within 24 months.”
Source: Elizabeth Holmes, 2014 Theranos Investor Pitch Deck
Red flags detectable at decision time
- No peer-reviewed validation of the Edison device had been published or submitted to any scientific journal
- Board of directors included prominent political figures (Kissinger, Shultz, Mattis) but zero medical device or diagnostics experts
- Walgreens partnership agreement was signed without Walgreens conducting independent testing of the technology
- Internal whistleblower complaints about device accuracy were dismissed and met with legal threats rather than investigation
Cognitive biases the platform would have flagged
Hypothetical analysis
A decision intelligence platform would have flagged the complete absence of peer-reviewed evidence for a medical device claiming 200+ test capabilities as a critical validation gap. The board composition—heavy on political authority figures, devoid of diagnostics expertise—matches the halo effect and authority bias pattern where prestige substitutes for domain competence. The platform would have recommended independent third-party testing as a mandatory prerequisite before any partnership or investment commitment.
Biases present in the decision
Toxic combinations
- Yes Committee
- Echo Chamber
- Golden Child
Reference class base rates
Across all 146 curated case studies in our library:
Lessons learned
- A prestigious board (Kissinger, Shultz, Mattis) without domain expertise creates authority bias without substantive oversight.
- Confirmation bias led investors to accept curated demos rather than demanding rigorous independent validation.
- When a company aggressively litigates against whistleblowers rather than addressing their claims, it signals systemic deception.
Source: John Carreyrou, "Bad Blood: Secrets and Lies in a Silicon Valley Startup" (2018); SEC v. Theranos complaint (2018) (News Investigation)
See what we'd flag in your next strategic memo.
Upload a strategic memo or board deck. Get the same hindsight-stripped analysis you just saw for Theranos, on your own high-stakes call, in under 60 seconds.
Or leave your email, we'll run a strategic memo of your choosing and send the readout within a business day.
Ready to audit your own memo right now? Create a free account →